Retrospective analysis of surgically treated pT4b gastric cancer with pancreatic head invasion

Table 1 Clinicopathological features of patients undergoing gastrectomy plus pancreatectomy and palliative gastrectomy alone

Variable	GP group, (n = 24) (%)	GA group, (n = 52) (%)	P value
Gender			0.486
Male	22 (91.7)	43 (82.7)
Female	2 (8.3)	9 (17.3)
Age (yr)			0.254
< 65	16 (66.7)	41 (78.8)
≥ 65	8 (33.3)	11 (21.2)
BMI (kg/m2)	23.5 ± 3.5	23.2 ± 3.3	0.779
ASA score			0.45
< 3	16 (66.7)	39 (75.0)
≥ 3	8 (33.3)	13 (25.0)
Neoadjuvant chemotherapy			< 0.001
Yes	10 (41.7)	44 (84.6)
No	14 (58.3)	8 (15.4)
Postoperative therapy			0.199
Chemotherapy	11 (45.8)	32 (61.5)
Chemoradiotherapy	13 (54.2)	20 (38.5)
Preoperative albumin (g/L)	37.9 ± 4.9	36.3 ± 5.1	0.083
Preoperative hemoglobin (g/L)	119.0 ± 28.2	108.3 ± 26.5	0.058
Linitis plastica			0.059
Yes	1 (4.2)	11 (21.2)
No	23 (95.8)	41 (78.8)
Borrmann type			0.312
I	1 (4.2)	1 (1.9)
II	8 (33.3)	18 (34.6)
III	14 (58.3)	23 (44.2)
IV	1 (4.2)	10 (19.2)
Tumor size (cm)	9.3 ± 2.3	6.7 ± 1.9	< 0.001
Histological type			0.945
Poorly differentiated	20 (83.3)	43 (82.7)
Well–moderately differentiated	4 (16.7)	9 (17.3)
Pathological N stage			0.03
N0	0 (0.0)	0 (0.0)
N1	0 (0.0)	0 (0.0)
N2	5 (20.8)	17 (32.7)
N3a	5 (20.8)	16 (30.8)
N3b	14 (58.3)	19 (36.5)
Lymphovascular invasion			0.168
Yes	22 (91.7)	41 (78.8)
No	2 (8.3)	11 (21.2)
Neural invasion			0.638
Yes	17 (70.8)	34 (65.4)
No	7 (29.2)	18 (34.6)
Surgical margin			< 0.001
R0	21 (87.5)	0 (0.0)
R1	3 (12.5)	52 (88.5)

Values are percentages or mean ± SD. GA: Gastrectomy alone; GP: Gastrectomy plus pancreatectomy; BMI: Body mass index; ASA: American Society of Anesthesiologists.